摘要
目的:观察分析化疗与放化疗对Ⅰb-Ⅱa期子宫颈癌术后有危险因素患者预后的影响。方法:选取我院妇产科收治的行子宫颈癌手术治疗且有术后有危险因素的Ⅰb-Ⅱa期子宫颈癌患者共105例为研究对象,根据术后辅助治疗方法的不同分为化疗组(51例)和放化疗组(54例),随访观察分析其1年不良反应情况及3年、5年盆腔复发率、远处转移率和生存率。结果:两组不良反应发生率无明显差异(P>0.05),放化疗组3年盆腔复发率为1.85%,远低于化疗组的15.69%,其3年生存率为98.15%,明显高于化疗组的82.35%;其5年盆腔复发率、远处转移率分别为3.70%、5.56%,远低于化疗组的21.57%、19.61%;其5年生存率为85.19%,明显高于化疗组的74.51%,上述差异均具有统计学意义(P<0.05)。结论:放化疗治疗可改善Ⅰb-Ⅱa期子宫颈癌术后有危险因素患者预后、提高生存率,值得临床推广。
Objectives： To observe and analyze the effect of chemotherapy and chemoradiotherapy for stageⅠb- Ⅱa cervical carcinoma with risk factors. Methods： 105 cases of stageⅠb- Ⅱa cervical carcinoma patients with risk factors in our hospital were chosen. They were successfully operated and divided into chemotherapy group（ n = 51） and chemoradiotherapy group（ n = 54） after operation. Difference in the incidence of 1- year adverse reactions,3- year and 5- year pelvic recurrence rates,distant metastatic rates and survival rates of the two groups was followed up and compared. Results： Difference in the incidence of adverse reactions of two groups was not significant（ P〈0. 05）. The 3- year pelvic recurrence rate of chemoradiotherapy group was 1. 85%,lower than 15. 69%of the chemotherapy group. The 3- year survival rate was 98. 15%,higher than 82. 35% of the chemotherapy group. The 5- year pelvic recurrence rates and distant metastatic rates were 3. 70%,5. 56%,lower than 21. 57%and 19. 61% of the chemotherapy group; the 5- year survival rates was 85. 19%,higher than 74. 51% of the chemotherapy group（ P〈0. 05）. Conclusion： Chemotherapy treatment for stageⅠb- Ⅱa cervical carcinoma with risk factors can improve the prognosis and survival rate,worthy of promotion.
出处
《中国性科学》
2016年第6期49-52,共4页
Chinese Journal of Human Sexuality
基金
湖北省重点实验室2014年度开放基金项目(SB201405)
关键词
子宫颈癌
化疗
放化疗
预后
Cervical carcinoma
Chemotherapy
Chemoradiotherapy
Prognosis
